Dr. Suyog Mehta is a highly experienced and strategically influential pharmaceutical leader, serving as Senior Vice President and Head of Medical Affairs & Clinical Research for India & Emerging Markets at Sun Pharmaceutical Industries Ltd., India’s largest drugmaker and a globally recognized pharmaceutical enterprise. In this role, he oversees medical strategy, evidence generation, and clinical research programs that anchor the company’s therapeutic portfolio and ensure scientific excellence across one of the world’s most dynamic healthcare markets.

With a robust medical foundation comprising an M.B.B.S. and M.D., Dr. Mehta combines deep clinical insight with strategic leadership in medical affairs. Prior to joining Sun Pharma in 2020, he built a broad and impactful career across leading pharmaceutical companies, including significant leadership roles at Dr. Reddy’s Laboratories and Johnson & Johnson, where he honed his expertise in medical strategy, regulatory collaboration, pharmacovigilance, clinical development, and cross-functional scientific engagement.

At Sun Pharma, Dr. Mehta has been instrumental in shaping and advancing the company’s medical affairs vision, driving evidence-based decision-making that supports both product life-cycle management and patient-centric outcomes. Under his guidance, the team has led rigorous clinical studies, fostered partnerships with healthcare professionals and investigators, and contributed to a portfolio of research involving tens of thousands of patients across hundreds of centers in recent years—efforts that have been recognized with prestigious industry awards for excellence in research and patient impact.

Known for his collaborative leadership style and commitment to scientific integrity, Dr. Mehta champions the integration of medical insight into strategic business priorities, ensuring that clinical evidence, real-world data, and robust medical communication inform Sun Pharma’s contributions to healthcare. His work exemplifies a mission to elevate standards of care by bridging clinical evidence with therapeutic innovation and patient-focused practice across India and the broader emerging markets.